PubMed Health⌕ Search

Biomedical subjects

M Luque Otero

Publications and source records attributed to M Luque Otero.

28 records · Page 2Linked to original sources
PubMed1982

Captopril in the treatment of mild essential hypertension.

1 Among 34 patients with mild essential hypertension treated for four weeks with captopril alone the blood pressure of 47% returned to normal. By the end of the fourth week chlorthalidone had been added to captopril in 18 of the patients; 15 then achieved normal blood pressure, and only three failed to achieve diastolic blood pressures of under 100 mm Hg. 2 Among the 16 patients who continued to take captopril alone after the fourth week all achieved a return to normal blood pressure during the next 12 months of treatment. 3 Side effects of captopril were essentially limited to rash, taste alteration, and nausea and vomiting, which were usually mild and transient.

Adult↗
PubMed1981

[The effect of therapeutic diuresis in carbohydrate tolerance in essential hypertension (author's transl)].

Carbohydrate tolerance was studied in ten patients with essential hypertension, both before and after one year of treatment with a diuretic: bumethanide. No significant differences were found in glucose and insulin values. Results show hyperglycemia aggravation to be minimal with bumethanide, although it is necessary to repeat determinations after several years of treatment as it has been demonstrated that hyperglycemia is aggravated in patients with essential hypertension after several years treatment with diuretics.

Adult↗
PubMedDate not supplied

Severe hypertension in the Spanish population. Association with specific HLA antigens.

There is now increasing evidence for immunological changes in essential hypertension. Immunological response is determined in part by genes linked to the HLA system. It has been reported a positive association between HLA B15 and the risk for cerebral events in essential hypertensive (EH) patients. We studied the distribution of HLA antigens in 128 EH (age range, 13-85 years) and 1000 normotensive controls. EH were classified in accordance with the World Health Organization (WHO) criteria: in WHO Stages I and II, there were 100 patients; in WHO Stage III, there were 28 patients. HLA-A and B antigens of peripheral blood lymphocytes were studied according to the microlymphocytotoxicity test. The results were compared by chi-square analysis, and the p value was multiplied by the number of antigens studied at each locus, to avoid overestimation of an association. Frequency of HLA-BW 22 was higher in EH compared with controls (5.4% vs 1.2%, p less than 0.01). Frequency of HLA-B12 in EH with WHO Stage III hypertension (64.2%) was significantly increased compared either with EH in WHO Stage I or II (29%, p less than 0.01) or the control group (26.9% p less than 0.001). The incidence of HLA-B15 antigen in the whole hypertensive group was 3.1%, lower than in normotensive controls (6.4%, p less than 0.8). None of the patients with WHO Stage III hypertension had the HLA-B15 antigen. In conclusion, the results seemed to indicated that the Spanish population had an association between HLA-B12 and severe hypertension.

Adult↗